# Title

 Food and Drugs. PART 13—PUBLIC HEARING BEFORE A PUBLIC BOARD OF INQUIRY


# ID

 CFR-2018-title21-vol1.Pt. 13


# Structured Analysis Summary

| Type        | Values                                                            |
|:------------|:------------------------------------------------------------------|
| Constraints | ['within', 'at least', 'after', 'before', 'more than']            |
| Duration    | ['30.0 day', '10.0 day', '15.0 day']                              |
| Condition   | ['until', 'not subject to', 'unless', 'subject to', 'when', 'if'] |
| Entities    | ['Internal', 'Scope', 'Inquiry', 'Food', 'Record', 'Board']       |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                       |
|:--------------|:--------------------------------------------------------------------------------------------------------------|
| before        | 13—PUBLIC HEARING BEFORE A PUBLIC BOARD OF INQUIRY. before                                                    |
| before        | the public interest to hold a public hearing before a Public Board of Inquiry (Board) with respect            |
| before        | the public interest to hold a public hearing before a Public Board of Inquiry (Board) with respect            |
| before        | the public interest to hold a public hearing before a Public Board of Inquiry (Board) with respect            |
| before        | the public interest to hold a public hearing before a Public Board of Inquiry (Board) with respect            |
| before        | Notice of a hearing  before  a Board.                                                                         |
| within        | of five nominees for members of the Board. within                                                             |
| before        | the center of FDA responsible for a matter before a Board, the other parties to the proceeding,               |
| within        | criteria established in paragraph (a) of this section. within                                                 |
| before        | event that it becomes relevant to any issue before  a court.                                                  |
| after         | three qualified persons as members of a Board. after                                                          |
| before        | Representatives of the participants in any proceeding  before a Board, including any members of the office    |
| before        | of the existing administrative record of the proceeding. before                                               |
| within        | under paragraph (a)(1) of this section is incomplete. within                                                  |
| after         | Board may not hold its first hearing until after all participants have submitted the information required by  |
| at least      | of the first hearing is to be published at least 15 days in advance and the hearing will                      |
| more than     | A participant's presentation may be made by  more than  one person.                                           |
| within        | rebuttal information and views in accordance with &#167;&#8201;13.20. within                                  |
| after         | (e) Within the time specified by the Board  after its first hearing, participants may submit written rebuttal |
| at least      | location of any hearing is to be published at least  15 days in advance.                                      |
| at least      | members are to be present at every hearing. at least                                                          |
| before        | (a) The administrative record of a hearing  before a Board consists of the following: (1) All                 |
| before        | record to receive further evidence at any time before  filing an initial decision.                            |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                        |
|:-----------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 30.0 day   | (b) Within 30 days of publication of the notice of hearing, the director of the center of FDA responsible for a matter before a Board, the other parties to the proceeding, and any person whose petition was granted and is the subject of the hearing, shall each submit to the Division of Dockets Management the names and full curricula vitae of five nominees for members of the Board. |
| 10.0 day   | Within 10 days of receipt of the lists of nominees, such persons may submit comments to the Division of Dockets Management on whether the nominees of the other persons meet the criteria established in paragraph (a) of this section.                                                                                                                                                        |
| 15.0 day   | Notice of the time and location of the first hearing is to be published at least 15 days in advance and the hearing will be open to the public.                                                                                                                                                                                                                                                |
| 15.0 day   | Notice of the time and location of any hearing is to be published at least 15 days in advance.                                                                                                                                                                                                                                                                                                 |


## Condition

| Condition      | Context                                                                                                                      |
|:---------------|:-----------------------------------------------------------------------------------------------------------------------------|
| subject to     | of this chapter a matter before FDA is subject to a hearing before a Board; or (c) Under                                     |
| if             | or (b), all applicable information described in &#167;&#8201;12.32(e). if                                                    |
| if             | notice, or the notice will refer to it if the document has already been published in the                                     |
| if             | &#167;&#8201;13.1(c), all of the information described in &#167;&#8201;12.32(e). if                                          |
| subject to     | relevant to the issues to be considered, are subject to the conflict of interest rules applicable to special                 |
| if             | the Commissioner is unable to find a qual if ied person with no conflict of interest from                                    |
| if             | the Commissioner is unable to find a qual if ied person with no conflict of interest from                                    |
| if             | this section, the Commissioner may choose a qual if ied member without further consultation with that person.                |
| subject to     | the proceeding and is not an advisory committee subject to the requirements of the Federal Advisory Committee Act            |
| subject to     | (a) The proceeding of a Board are  subject to the provisions of &#167;&#8201;10.55 relating to separation of                 |
| when           | the supplement was not known or reasonably available when the initial submission was made or that the                        |
| until          | A Board may not hold its first hearing until after all participants have submitted the information required                  |
| if             | other participant may be permitted to ask questions if the Chairman determines that it will help resolve                     |
| if             | The Chariman will then schedule a second hearing,  if  requested and just                                                    |
| if             | and any subsequent hearing, will be called only if the Chairman concludes that it is needed to                               |
| not subject to | and comments submitted on them under &#167;&#8201;13.10(b)(3) are not subject to disclosure unless they become an issue in a |
| unless         | them under &#167;&#8201;13.10(b)(3) are not subject to disclosure unless  they become an issue in a court proceeding.        |


## Entities

| Entities   | Context                                                                                          |
|:-----------|:-------------------------------------------------------------------------------------------------|
| Food       | Food  and Drugs.                                                                                 |
| Scope      | Scope .                                                                                          |
| Inquiry    | a public hearing before a Public Board of Inquiry (Board) with respect to any matter before FDA; |
| Board      | to hold a public hearing before a Public Board  of Inquiry (                                     |
| Internal   | Internal memoranda reflecting the deliberative process, and attorney work                        |
| Record     | Record  for administrative decision.                                                             |


